• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Alector Announces Appointment of Gary Romano, M.D., Ph.D., as Chief Medical Officer

    3/29/22 4:05:00 PM ET
    $ALEC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ALEC alert in real time by email

    SOUTH SAN FRANCISCO, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the appointment of Gary Romano, M.D., Ph.D., as Chief Medical Officer. In this role, Dr. Romano will lead the company's global clinical development strategy, including oversight of the clinical development, clinical operations, biometrics and digital science, and medical affairs functions. Dr. Romano will report to Sara Kenkare-Mitra, Ph.D., President and Head of Research and Development of Alector. Dr. Romano's appointment is effective May 23, 2022.

    "We are delighted to welcome Gary to our executive leadership team," said Dr. Kenkare-Mitra. "He is a board-certified neurologist, neurodegeneration expert, and recognized clinical leader in the industry with a demonstrated track record in progressing the development of therapeutics for multiple neuroscience indications. Gary's extensive research and medical experience coupled with his doctorate degree in Neuroscience will further enable our vision of seamless integration of our drug discovery, translational and clinical development areas. I believe Gary's clinical vision and leadership will prove to be invaluable as we continue to advance our rich clinical pipeline toward late-stage studies and bring novel drug candidates into the clinic."

    Alector is deeply grateful to Sam Jackson, M.D., M.B.A., Senior Vice President, Clinical Sciences, who served as interim CMO since September 7, 2021. Sam is pursuing a new opportunity outside of Alector though he will continue to consult with Alector. Dr. Kenkare-Mitra added, "Sam has been an important contributor and leader at Alector, playing an instrumental role in the development of AL001, the expansion of our clinical development function, and the advancement of our robust pipeline. We thank Sam for his impactful contributions to Alector and wish him well in his future endeavors."

    "Alector's deep scientific expertise in microglial biology and ongoing rigorous clinical interrogation of compelling genetically-validated neuro-immune targets for neurodegenerative diseases are trailblazing a novel and promising approach to treatment that provides new hope for those with diseases such as frontotemporal dementia, Alzheimer's disease, ALS and Parkinson's disease," said Dr. Romano. "My passion is to make a meaningful impact in the lives of patients and families suffering from neurodegenerative diseases through the development of transformative treatments. Joining Alector is a natural next step for me, and I look forward to working with the team to develop effective therapies that preserve brain health."

    Dr. Romano joins Alector with more than 25 years of experience in neurodegenerative disease, including 18 years in industry roles at Merck, the Janssen Pharmaceutical Companies of Johnson & Johnson, and Passage Bio. Dr. Romano served as the Chief Medical Officer of Passage Bio until May 2021, where he was responsible for the clinical development of gene therapies targeting rare monogenic central nervous system disorders and achieved Investigational New Drug and Clinical Trial Application clearances for three gene therapies. Prior to Passage Bio, Dr. Romano oversaw clinical development of the neurodegenerative disease portfolio for more than five years at Janssen as the Deputy Leader, Neurodegenerative Disease Area and Head of Development, Neurodegenerative Disease. He previously held other leadership positions at Janssen, including Head of Neuroscience Biomarkers and Head of Early Clinical Development. Earlier in his career, Dr. Romano served as the Alzheimer's Disease Therapeutic Area Group Co-Leader and Leader, Neuroscience Experimental Medicine at Merck.

    Dr. Romano earned a B.S. in Biology from Trinity College, a Ph.D. in Molecular Neurobiology from Rockefeller University, and an M.D. from The Johns Hopkins University School of Medicine. He completed his medical internship, neurology residency and neuromuscular fellowship at the University of Pennsylvania. He has served on the executive committee of the Innovative Medicines Initiative - European Prevention of Alzheimer's Disease, and as the industry co-chair of the Critical Path Institute Coalition Against Alzheimer's Disease. Dr. Romano currently serves on the board of directors of the ALS Hope Foundation and is an adjunct member of the neurology department at the Lewis Katz School of Medicine at Temple University.

    About Alector

    Alector is a clinical-stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. Alector has discovered and is developing a broad portfolio of innate immune system programs, designed to functionally repair genetic mutations that cause dysfunction of the brain's immune system and enable the rejuvenated immune cells to counteract emerging brain pathologies. Alector's immuno-neurology product candidates are supported by biomarkers and target genetically defined patient populations in frontotemporal dementia and Alzheimer's disease. This scientific approach is also the basis for the company's immuno-oncology programs. Alector is headquartered in South San Francisco, California. For additional information, please visit www.alector.com.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements regarding our business plans, personnel arrangements, and advancement of our clinical pipeline. Such statements are subject to numerous risks and uncertainties, including but not limited to risks and uncertainties as set forth in Alector's Annual Report on Form 10-K, as filed on February 24, 2022 with the Securities and Exchange Commission ("SEC"), as well as the other documents Alector files from time to time with the SEC. These documents contain and identify important factors that could cause the actual results for Alector to differ materially from those contained in Alector's forward-looking statements. Any forward-looking statements contained in this press release speak only as of the date hereof, and Alector specifically disclaims any obligation to update any forward-looking statement, except as required by law.

    Contacts:

    1AB (media)

    Dan Budwick

    973-271-6085 

    [email protected]

    Argot Partners (investors)

    Eric Kasper/Carrie McKim

    Argot Partners

    212.600.1902

    [email protected]



    Primary Logo

    Get the next $ALEC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ALEC

    DatePrice TargetRatingAnalyst
    12/17/2024$9.00 → $2.50Outperform → Neutral
    Mizuho
    12/16/2024$4.00Buy → Hold
    Stifel
    12/4/2024$9.00 → $1.00Neutral → Underperform
    BofA Securities
    11/29/2024$35.00 → $7.00Buy
    H.C. Wainwright
    11/26/2024$10.00 → $3.00Equal-Weight → Underweight
    Morgan Stanley
    12/14/2023$8.00 → $15.00Hold → Buy
    Stifel
    12/12/2023$12.00Buy
    Deutsche Bank
    9/25/2023$4.00Sell
    Goldman
    More analyst ratings

    $ALEC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Alector Reports First Quarter 2025 Financial Results and Provides Business Update

      Topline data from pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in FTD-GRN on track for Q4 2025 Completed enrollment in PROGRESS-AD Phase 2 clinical trial of AL101 in early Alzheimer's disease Continuing to pursue Alector Brain Carrier programs, including the company's anti-amyloid beta antibody and its GCase enzyme replacement therapy Extending runway into the second half of 2027, with $354.6 million in cash, cash equivalents, and investments SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, toda

      5/8/25 4:05:00 PM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Alector to Participate in Upcoming Healthcare Conferences

      SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that management will participate in the following upcoming investor conferences: Bank of America Securities Health Care Conference (Las Vegas, Nevada) Tuesday, May 13, 2025, at 2:20 p.m. PT, corporate presentation H.C. Wainwright 3rd Annual BioConnect Investor Conference (New York, New York) Tuesday, May 20, 2025, at 12:00 p.m. ET, fireside chat A webcast of each conference presentation will be available on the "Events & Presentations" page w

      5/6/25 8:00:00 AM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Alector Announces Completion of Enrollment in the PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Individuals with Early Alzheimer's Disease

      --76-week trial is evaluating the safety and efficacy of a progranulin-elevating candidate in slowing disease progression-- --Enrollment completed ahead of schedule-- SOUTH SAN FRANCISCO, Calif., April 17, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced the completion of enrollment in PROGRESS-AD, a 76-week Phase 2 clinical trial evaluating the safety and efficacy of AL101/GSK4527226 in slowing disease progression in individuals with early Alzheimer's disease (AD). Alector and GSK are co-developing AL101, an investigational hum

      4/17/25 8:00:00 AM ET
      $ALEC
      $GSK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $ALEC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Alector Inc.

      SC 13G - Alector, Inc. (0001653087) (Subject)

      12/6/24 5:30:28 PM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Alector Inc.

      SC 13G/A - Alector, Inc. (0001653087) (Subject)

      11/12/24 7:21:57 PM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Alector Inc.

      SC 13G/A - Alector, Inc. (0001653087) (Subject)

      11/7/24 12:41:31 PM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ALEC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Alector downgraded by Mizuho with a new price target

      Mizuho downgraded Alector from Outperform to Neutral and set a new price target of $2.50 from $9.00 previously

      12/17/24 7:23:27 AM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Alector downgraded by Stifel with a new price target

      Stifel downgraded Alector from Buy to Hold and set a new price target of $4.00

      12/16/24 6:41:43 AM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Alector downgraded by BofA Securities with a new price target

      BofA Securities downgraded Alector from Neutral to Underperform and set a new price target of $1.00 from $9.00 previously

      12/4/24 7:19:54 AM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ALEC
    Leadership Updates

    Live Leadership Updates

    See more
    • Alector Reports First Quarter 2024 Financial Results and Provides Business Update

      Data from INVOKE-2, evaluating the most advanced TREM2 candidate in clinical development for early Alzheimer's disease, on track for Q4 2024 Strengthened leadership team with key appointments: Neil Berkley, M.S., M.B.A., named Chief Business Officer; Errol De Souza, Ph.D., and Mark Altmeyer, M.B.A., join Board of Directors $562.1 million in cash, cash equivalents and investments provide runway through 2026 SOUTH SAN FRANCISCO, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today reported first quarter 2024 financial results and recent portfolio and business updates. As of March 31, 202

      5/8/24 4:05:00 PM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Alector Announces Appointment of Gary Romano, M.D., Ph.D., as Chief Medical Officer

      SOUTH SAN FRANCISCO, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the appointment of Gary Romano, M.D., Ph.D., as Chief Medical Officer. In this role, Dr. Romano will lead the company's global clinical development strategy, including oversight of the clinical development, clinical operations, biometrics and digital science, and medical affairs functions. Dr. Romano will report to Sara Kenkare-Mitra, Ph.D., President and Head of Research and Development of Alector. Dr. Romano's appointment is effective May 23, 2022. "We are delighted to welcome Gary to our executive leadership tea

      3/29/22 4:05:00 PM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Alector Announces Appointment of Marc Grasso, M.D., as Chief Financial Officer

      SOUTH SAN FRANCISCO, Calif., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company pioneering the discovery and development of immuno-neurology therapeutics, today announced the appointment of Marc Grasso, M.D., as Chief Financial Officer (CFO). Dr. Grasso brings extensive biotechnology industry leadership experience, including a successful track record in finance, corporate development and strategic leadership. As Alector's CFO, Dr. Grasso will lead all aspects of the company's financial operations and play a critical role in supporting corporate strategy. Dr. Grasso will report to Arnon Rosenthal, Ph.D., Chief Executive Officer of Alector. 

      2/7/22 8:30:00 AM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ALEC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Scheller Richard H was granted 15,833 shares, increasing direct ownership by 31% to 66,666 units (SEC Form 4)

      4 - Alector, Inc. (0001653087) (Issuer)

      5/2/25 6:00:09 PM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Financial Officer Grasso Marc sold $26,547 worth of shares (18,091 units at $1.47), decreasing direct ownership by 5% to 312,560 units (SEC Form 4)

      4 - Alector, Inc. (0001653087) (Issuer)

      3/5/25 4:05:13 PM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Executive Officer Rosenthal Arnon sold $59,176 worth of shares (40,330 units at $1.47), decreasing direct ownership by 2% to 2,466,744 units (SEC Form 4)

      4 - Alector, Inc. (0001653087) (Issuer)

      3/5/25 4:05:18 PM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ALEC
    Financials

    Live finance-specific insights

    See more
    • Alector Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

      Topline data from the pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in FTD-GRN expected by Q4 2025 Anticipate completing enrollment in the PROGRESS-AD Phase 2 clinical trial of AL101/GSK4527226 in participants with early Alzheimer's disease by mid-2025 Applying Alector Brain Carrier to advance therapeutic candidates, including those targeting amyloid beta and replacing GCase $413.4 million in cash, cash equivalents and investments provide runway through 2026 Management to host conference call and webcast today at 4:30 p.m. ET/1:30 p.m. PT SOUTH SAN FRANCISCO, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a late-stage clinical biotechnology company

      2/26/25 4:05:00 PM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Alector to Host Fourth Quarter and Full-Year 2024 Earnings Conference Call

      SOUTH SAN FRANCISCO, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced it will host a conference call and webcast on Wednesday, February 26, 2025, at 4:30 p.m. ET to discuss results for the fourth quarter ended December 31, 2024, and provide a full-year business update. A press release detailing fourth quarter results will be issued prior to the call. The event will be webcast live under the investor relations section of Alector's website at https://investors.alector.com/events-and-presentations/events, and follo

      2/19/25 4:05:00 PM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Alector Reports on Recent Progress and Outlines Strategic Priorities for 2025

      Continue to advance preclinical and research pipeline, including key programs selectively combined with Alector Brain Carrier, enhancing the company's commitment to developing genetically-validated therapies for neurodegeneration Topline data from the pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in FTD-GRN expected by Q4 2025 Completion of enrollment in the PROGRESS-AD Phase 2 trial of AL101/GSK4527226 for early Alzheimer's disease anticipated in mid-2025, with approximately 75% target recruitment achieved $457.2 million in cash, cash equivalents and investments as of September 30, 2024, expected to fund operations through 2026 SOUTH SAN FRANCISCO, Calif., Jan. 13, 2025 (GLO

      1/13/25 8:00:00 AM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ALEC
    SEC Filings

    See more
    • SEC Form 10-Q filed by Alector Inc.

      10-Q - Alector, Inc. (0001653087) (Filer)

      5/8/25 4:15:17 PM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Alector Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Alector, Inc. (0001653087) (Filer)

      5/8/25 4:10:08 PM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by Alector Inc.

      DEFA14A - Alector, Inc. (0001653087) (Filer)

      4/24/25 4:02:03 PM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care